Bypassing the guardian: regulated cell death pathways in p53-mutant cancers

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Mutations in the tumor suppressor p53 occur in approximately 50% of human cancers.
• p53 mutations contribute to tumor metastasis and chemoresistance by disrupting cellular homeostasis and inhibiting regulated cell death (RCD) pathways.
• Effective cancer therapies often rely on activating RCD pathways to eliminate cancerous cells.

Purpose of the Study:

• To review emerging cancer therapeutics targeting RCD pathways in p53-mutant cancers.
• To discuss the mechanisms of RCD activation and the impact of p53 mutations on these pathways.
• To highlight current pharmaceutical strategies for RCD activation in p53-mutant cancers.

Main Methods:

• Review of existing literature on RCD pathways and p53 mutations.
• Analysis of mechanisms underlying E2F1-dependent apoptosis, necroptosis, mitochondrial permeability transition-driven necrosis, and ferroptosis.
• Examination of current and emerging pharmaceutical strategies for targeting these RCD pathways.

Main Results:

• p53 mutations dysregulate cellular homeostasis and prevent RCD activation, promoting cancer cell survival.
• Certain RCD pathways may be particularly susceptible to activation in p53-mutant cancers.
• Emerging therapeutics aim to reactivate these RCD pathways to eliminate cancer cells.

Conclusions:

• Targeting specific RCD pathways presents a promising therapeutic avenue for p53-mutant cancers.
• Understanding the interplay between p53 status and RCD mechanisms is crucial for developing effective treatments.
• Pharmaceutical strategies focusing on apoptosis, necroptosis, necrosis, and ferroptosis hold potential for clinical application.